SEPN:NASDAQSepterna, Inc. Analysis
Data as of 2026-08-02 - not real-time
$34.45
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Septerna, Inc. is trading at $34.45, comfortably above its 20‑day SMA of $34.24 and the 200‑day SMA of $27.25, indicating a short‑term bullish bias despite a bearish MACD histogram. The stock sits midway between a support level of $30.55 and a resistance ceiling of $38.04, while the Fear & Greed Index at 92.9 signals extreme market optimism.
Fundamentally, the company reports a staggering 120% YoY revenue surge to $72.3 M, backed by $347 M of cash and a modest $23 M debt load, yet it remains loss‑making with a –50% operating margin and negative EPS. The DCF‑derived fair value of $25.83 suggests the market is pricing in a roughly 30% premium, and analysts’ consensus of a “strong buy” with a $45 target reflects confidence in its pipeline—particularly the potential first‑in‑class hypoparathyroidism therapy highlighted in recent coverage.
Fundamentally, the company reports a staggering 120% YoY revenue surge to $72.3 M, backed by $347 M of cash and a modest $23 M debt load, yet it remains loss‑making with a –50% operating margin and negative EPS. The DCF‑derived fair value of $25.83 suggests the market is pricing in a roughly 30% premium, and analysts’ consensus of a “strong buy” with a $45 target reflects confidence in its pipeline—particularly the potential first‑in‑class hypoparathyroidism therapy highlighted in recent coverage.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Mixed technical signals (bullish SMA alignment vs. bearish MACD)
- High 30‑day volatility (~64%) and decreasing volume
- Current price above DCF fair value, limiting upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 120% revenue growth and strong cash position ($347 M)
- Strategic partnership with Novo Nordisk and promising pipeline
- Analyst consensus of strong‑buy with median target $43
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Potential first‑in‑class oral GPCR therapies addressing unmet needs
- Long‑run value creation despite current losses, supported by positive operating cash flow
- Low geographic concentration (U.S.) and manageable debt‑to‑equity ratio
Key Metrics & Analysis
Financial Health
Revenue Growth12011.00%
Profit Margin-49.88%
P/E Ratio-13.0
ROE-9.26%
ROA-8.49%
Debt/Equity6.10
P/B Ratio4.1
Op. Cash Flow$107.9M
Free Cash Flow$24.0M
Industry P/E29.2
Technical Analysis
TrendBullish
RSI52.4
Support$30.55
Resistance$38.04
MA 20$34.24
MA 50$33.30
MA 200$27.25
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Fair Value$25.83
Target Price$45.00
Upside/Downside30.62%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.97
Volatility64.26%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.